Sharechat Logo

Pacific Edge first-half loss widens on push for US growth; sales jump 67%

Thursday 24th November 2016

Text too small?

Pacific Edge reported a wider first-half loss as the bladder cancer test company hired more salespeople in the US and spent more on research, sales & marketing.

The net loss was $11.3 million in the six months ended Sept. 30, from a loss of $7 million a year earlier, the Dunedin-based company said in a statement. Operating revenue climbed to about $3 million from $1.8 million.

Pacific Edge shares have gained about 2 percent this year and were last at 53 cents. They jumped about 20 percent on Nov. 14 after the company said a study of its Cxbladder Triage test, used to rule out patients with a low risk of bladder cancer, was evaluated in a large study of patients of not-for-profit US healthcare provider Kaiser Permanente and found to a negative predictive value of 98.5 percent, matching previous studies. Cxbladder Triage only became available in the US late in the first half and the bulk of the sales to date have come from its Cxbladder Detect product. A third product, the Cxbladder Monitor, will become available in the second half.

“We are seeing a steady increase in customer numbers and have a growing number of clinicians trialling and using our products through user programmes, which is an essential part of the clinical adoption cycle," said chief executive David Darling. "We expect to report a strong second half uplift in line with annual trends.”

Operating expenses rose to $15 million from $9.7 million and included $2.93 million for the employee incentive scheme, and research costs of $2.47 million, up from $1.9 million a year earlier. Wages rose 14 percent to $4.2 million.

The company said the first-half loss was in line with its expectations. The majority of revenue comes from existing customers, mostly smaller urologist practices, with no contribution yet from the recent new customers - the Veterans Administration (VA) and Tricare, it said. Pacific Edge said it had to contend with a stronger kiwi dollar in the first half and reduce grant income from Callaghan Innovation as a result of changes to the funding body's growth grant scheme.

In its home market of New Zealand, sales rose 187 percent, it said.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

POT Financial Results for the year to 30 June 2025
MOVE FY25 Results for the year ended 30 June 2025
BPG - Completion of Retail Offer
Comvita releases results for the year ended 30 June 2025
August 29th Morning Report
Air New Zealand announces 2025 financial result
August 28th Morning Report
VSL - 2025 date of Annual Meeting of shareholders
WIN - Winton announces FY25 Annual Results
Meridian Energy Limited 2025 Full Year Financial Results